Trials / Withdrawn
WithdrawnNCT04087941
Efficacy and Safety of VM202 in Painful Diabetic Peripheral Neuropathy -The HOPES Trial
Hepatocyte Growth Factor for Opioid-Dependent Pain: Efficacy and Safety of VM202 in Painful Diabetic Peripheral Neuropathy (The HOPES Trial)
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Brigham and Women's Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
A double-blind, randomized, placebo-controlled, single-center, 12-month phase 2 study designed to assess the safety and efficacy of VM202 as a replacement for opioid analgesics in opioid-tolerant subjects with painful diabetic peripheral neuropathy (DPN).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | VM-202 | VM202 is a DNA plasmid that contains novel genomic cDNA hybrid human hepatocyte growth factor (HGF) coding sequence (HGF-X7) expressing two isoforms of HGF, HGF 728 and HGF 723. |
Timeline
- Start date
- 2019-11-01
- Primary completion
- 2022-12-01
- Completion
- 2022-12-01
- First posted
- 2019-09-12
- Last updated
- 2025-11-28
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04087941. Inclusion in this directory is not an endorsement.